Alto Neuroscience (ANRO) Competitors

$20.33 -1.47 (-6.72%)

Closing price 03:59 PM Eastern

Extended Trading

$20.44 +0.11 (+0.52%)

As of 05:30 PM Eastern

ANRO vs. RCUS, DNLI, DYN, GMTX, and ALMS

Should you buy Alto Neuroscience stock or one of its competitors? MarketBeat compares Alto Neuroscience with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Alto Neuroscience include Arcus Biosciences (RCUS), Denali Therapeutics (DNLI), Dyne Therapeutics (DYN), Gemini Therapeutics (GMTX), and Alumis (ALMS). These companies are all part of the "pharmaceutical products" industry.

How does Alto Neuroscience compare to Arcus Biosciences?

Alto Neuroscience (NYSE:ANRO) and Arcus Biosciences (NYSE:RCUS) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.

Alto Neuroscience has a net margin of 0.00% compared to Arcus Biosciences' net margin of -156.36%. Alto Neuroscience's return on equity of -47.22% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alto Neuroscience	N/A	-47.22%	-38.81%
Arcus Biosciences	-156.36%	-68.97%	-35.27%

Alto Neuroscience has a beta of 1.62, indicating that its stock price is 62% more volatile than the broader market. Comparatively, Arcus Biosciences has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market.

In the previous week, Alto Neuroscience had 2 more articles in the media than Arcus Biosciences. MarketBeat recorded 5 mentions for Alto Neuroscience and 3 mentions for Arcus Biosciences. Arcus Biosciences' average media sentiment score of -0.04 beat Alto Neuroscience's score of -0.19 indicating that Arcus Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alto Neuroscience	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arcus Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alto Neuroscience currently has a consensus target price of $35.25, suggesting a potential upside of 73.35%. Arcus Biosciences has a consensus target price of $33.89, suggesting a potential upside of 48.81%. Given Alto Neuroscience's stronger consensus rating and higher possible upside, equities research analysts clearly believe Alto Neuroscience is more favorable than Arcus Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alto Neuroscience	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.55

Alto Neuroscience has higher earnings, but lower revenue than Arcus Biosciences. Alto Neuroscience is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A
Arcus Biosciences	$247M	11.60	-$353M	-$3.18	N/A

92.9% of Arcus Biosciences shares are held by institutional investors. 11.3% of Alto Neuroscience shares are held by company insiders. Comparatively, 9.6% of Arcus Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Alto Neuroscience beats Arcus Biosciences on 9 of the 14 factors compared between the two stocks.

How does Alto Neuroscience compare to Denali Therapeutics?

Alto Neuroscience (NYSE:ANRO) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment and analyst recommendations.

Alto Neuroscience currently has a consensus price target of $35.25, suggesting a potential upside of 73.35%. Denali Therapeutics has a consensus price target of $35.00, suggesting a potential upside of 93.46%. Given Denali Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Denali Therapeutics is more favorable than Alto Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alto Neuroscience	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Denali Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87

Alto Neuroscience's return on equity of -47.22% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alto Neuroscience	N/A	-47.22%	-38.81%
Denali Therapeutics	N/A	-52.20%	-43.86%

Alto Neuroscience has a beta of 1.62, suggesting that its stock price is 62% more volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 0.99, suggesting that its stock price is 1% less volatile than the broader market.

In the previous week, Alto Neuroscience had 3 more articles in the media than Denali Therapeutics. MarketBeat recorded 5 mentions for Alto Neuroscience and 2 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 0.94 beat Alto Neuroscience's score of -0.19 indicating that Denali Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alto Neuroscience	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Denali Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

92.9% of Denali Therapeutics shares are owned by institutional investors. 11.3% of Alto Neuroscience shares are owned by insiders. Comparatively, 12.5% of Denali Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Alto Neuroscience has higher earnings, but lower revenue than Denali Therapeutics. Alto Neuroscience is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A
Denali Therapeutics	$330.53M	8.69	-$512.54M	-$2.88	N/A

Summary

Denali Therapeutics beats Alto Neuroscience on 9 of the 15 factors compared between the two stocks.

How does Alto Neuroscience compare to Dyne Therapeutics?

Alto Neuroscience (NYSE:ANRO) and Dyne Therapeutics (NASDAQ:DYN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk.

Alto Neuroscience presently has a consensus target price of $35.25, suggesting a potential upside of 73.35%. Dyne Therapeutics has a consensus target price of $35.00, suggesting a potential upside of 119.85%. Given Dyne Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Dyne Therapeutics is more favorable than Alto Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alto Neuroscience	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	3 Strong Buy rating(s)	2.94

Alto Neuroscience's return on equity of -47.22% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alto Neuroscience	N/A	-47.22%	-38.81%
Dyne Therapeutics	N/A	-58.28%	-46.77%

In the previous week, Dyne Therapeutics had 22 more articles in the media than Alto Neuroscience. MarketBeat recorded 27 mentions for Dyne Therapeutics and 5 mentions for Alto Neuroscience. Dyne Therapeutics' average media sentiment score of 0.45 beat Alto Neuroscience's score of -0.19 indicating that Dyne Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alto Neuroscience	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dyne Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alto Neuroscience is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.22	N/A

96.7% of Dyne Therapeutics shares are held by institutional investors. 11.3% of Alto Neuroscience shares are held by insiders. Comparatively, 14.1% of Dyne Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Alto Neuroscience has a beta of 1.62, meaning that its share price is 62% more volatile than the broader market. Comparatively, Dyne Therapeutics has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market.

Summary

Dyne Therapeutics beats Alto Neuroscience on 9 of the 14 factors compared between the two stocks.

How does Alto Neuroscience compare to Gemini Therapeutics?

Alto Neuroscience (NYSE:ANRO) and Gemini Therapeutics (NASDAQ:GMTX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, media sentiment, profitability, institutional ownership and risk.

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Alto Neuroscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A

Gemini Therapeutics' return on equity of -38.78% beat Alto Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alto Neuroscience	N/A	-47.22%	-38.81%
Gemini Therapeutics	N/A	-38.78%	-35.88%

Alto Neuroscience has a beta of 1.62, meaning that its share price is 62% more volatile than the broader market. Comparatively, Gemini Therapeutics has a beta of -0.12, meaning that its share price is 112% less volatile than the broader market.

75.4% of Gemini Therapeutics shares are held by institutional investors. 11.3% of Alto Neuroscience shares are held by company insiders. Comparatively, 12.9% of Gemini Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Alto Neuroscience had 5 more articles in the media than Gemini Therapeutics. MarketBeat recorded 5 mentions for Alto Neuroscience and 0 mentions for Gemini Therapeutics. Gemini Therapeutics' average media sentiment score of 0.00 beat Alto Neuroscience's score of -0.19 indicating that Gemini Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Alto Neuroscience	Neutral
Gemini Therapeutics	Neutral

Alto Neuroscience currently has a consensus target price of $35.25, indicating a potential upside of 73.35%. Given Alto Neuroscience's stronger consensus rating and higher probable upside, analysts plainly believe Alto Neuroscience is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alto Neuroscience	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Alto Neuroscience beats Gemini Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Alto Neuroscience compare to Alumis?

Alumis (NASDAQ:ALMS) and Alto Neuroscience (NYSE:ANRO) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, risk, analyst recommendations and valuation.

Alumis currently has a consensus target price of $40.30, suggesting a potential upside of 87.27%. Alto Neuroscience has a consensus target price of $35.25, suggesting a potential upside of 73.35%. Given Alumis' stronger consensus rating and higher possible upside, equities research analysts clearly believe Alumis is more favorable than Alto Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Alto Neuroscience	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Alto Neuroscience has a net margin of 0.00% compared to Alumis' net margin of -2,825.70%. Alto Neuroscience's return on equity of -47.22% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alumis	-2,825.70%	-88.79%	-70.72%
Alto Neuroscience	N/A	-47.22%	-38.81%

Alto Neuroscience has lower revenue, but higher earnings than Alumis. Alumis is trading at a lower price-to-earnings ratio than Alto Neuroscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alumis	$24.05M	113.82	-$243.32M	-$1.98	N/A
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A

Alumis has a beta of -0.31, suggesting that its share price is 131% less volatile than the broader market. Comparatively, Alto Neuroscience has a beta of 1.62, suggesting that its share price is 62% more volatile than the broader market.

In the previous week, Alumis had 16 more articles in the media than Alto Neuroscience. MarketBeat recorded 21 mentions for Alumis and 5 mentions for Alto Neuroscience. Alumis' average media sentiment score of 0.27 beat Alto Neuroscience's score of -0.19 indicating that Alumis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alumis	0 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alto Neuroscience	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Alumis beats Alto Neuroscience on 8 of the 14 factors compared between the two stocks.

Get Alto Neuroscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANRO vs. The Competition

Export

Metric	Alto Neuroscience	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$713.52M	$3.25B	$6.25B	$22.67B
Dividend Yield	N/A	2.33%	2.80%	4.12%
P/E Ratio	-8.40	18.70	20.58	29.47
Price / Sales	N/A	278.20	577.42	13.58
Price / Cash	N/A	55.27	27.48	18.80
Price / Book	4.18	6.57	9.68	4.54
Net Income	-$63.24M	$24.30M	$3.55B	$1.07B
7 Day Performance	-17.49%	-3.56%	-2.07%	-1.81%
1 Month Performance	-26.48%	-7.86%	-3.90%	-2.17%
1 Year Performance	694.30%	51.80%	29.39%	20.97%

Alto Neuroscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANRO Alto Neuroscience	2.6198 of 5 stars	$20.33 -6.7%	$35.25 +73.4%	+756.1%	$713.52M	N/A	N/A	N/A	Earnings Report Analyst Downgrade
RCUS Arcus Biosciences	3.0985 of 5 stars	$24.93 +0.3%	$33.33 +33.7%	+173.7%	$3.13B	$247M	N/A	500	Analyst Forecast
DNLI Denali Therapeutics	3.4367 of 5 stars	$19.46 -1.1%	$34.50 +77.3%	+33.5%	$3.09B	$330.53M	N/A	430
DYN Dyne Therapeutics	3.3262 of 5 stars	$18.37 -0.5%	$35.14 +91.3%	+39.8%	$3.04B	N/A	N/A	100	Analyst Upgrade
GMTX Gemini Therapeutics	N/A	$69.23 +1.4%	N/A	+39.0%	$3.00B	N/A	N/A	30	Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ANRO) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alto Neuroscience (ANRO) Competitors

ANRO vs. RCUS, DNLI, DYN, GMTX, and ALMS

How does Alto Neuroscience compare to Arcus Biosciences?

Summary

How does Alto Neuroscience compare to Denali Therapeutics?

Summary

How does Alto Neuroscience compare to Dyne Therapeutics?

Summary

How does Alto Neuroscience compare to Gemini Therapeutics?

Summary

How does Alto Neuroscience compare to Alumis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANRO vs. The Competition

Alto Neuroscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alto Neuroscience (ANRO) Competitors

ANRO vs. RCUS, DNLI, DYN, GMTX, and ALMS

How does Alto Neuroscience compare to Arcus Biosciences?

Is ANRO or RCUS more profitable?

Which has more risk & volatility, ANRO or RCUS?

Does the media prefer ANRO or RCUS?

Do analysts rate ANRO or RCUS?

Which has stronger valuation & earnings, ANRO or RCUS?

Do institutionals and insiders believe in ANRO or RCUS?

Summary

How does Alto Neuroscience compare to Denali Therapeutics?

Do analysts recommend ANRO or DNLI?

Is ANRO or DNLI more profitable?

Which has more risk & volatility, ANRO or DNLI?

Does the media refer more to ANRO or DNLI?

Do institutionals & insiders hold more shares of ANRO or DNLI?

Which has stronger earnings & valuation, ANRO or DNLI?

Summary

How does Alto Neuroscience compare to Dyne Therapeutics?

Do analysts rate ANRO or DYN?

Is ANRO or DYN more profitable?

Does the media refer more to ANRO or DYN?

Which has better valuation and earnings, ANRO or DYN?

Do institutionals and insiders hold more shares of ANRO or DYN?

Which has more risk & volatility, ANRO or DYN?

Summary

How does Alto Neuroscience compare to Gemini Therapeutics?

Which has preferable valuation & earnings, ANRO or GMTX?

Is ANRO or GMTX more profitable?

Which has more volatility and risk, ANRO or GMTX?

Do institutionals & insiders have more ownership in ANRO or GMTX?

Does the media prefer ANRO or GMTX?

Do analysts prefer ANRO or GMTX?

Summary

How does Alto Neuroscience compare to Alumis?

Do analysts prefer ALMS or ANRO?

Is ALMS or ANRO more profitable?

Which has higher valuation & earnings, ALMS or ANRO?

Which has more volatility & risk, ALMS or ANRO?

Does the media refer more to ALMS or ANRO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANRO vs. The Competition

Alto Neuroscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools